Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Accelerate Diagnostics, IncAXDX · Entity 78156 | Director | December 03, 2024 | December 03, 2024 |
| BIODESIX INCBDSX · Entity 6053 | Director · Chairman | September 30, 2026 | October 03, 2026 |
| STERICYCLE INCSRCL · Entity 80873 | Director | May 23, 2018 | May 25, 2018 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Accelerate Diagnostics, Inc
Report date December 03, 2024 · Filed December 03, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy John Patience Living Trust dated 7/23/1993 | 653,224 |
Reported balance
After 2024-12-03 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2024-12-03 · Purchase · Acquired 200,000 · Balance 653,224 F1: Represents shares purchased by the reporting person from Jack Schuler, a member of the issuer's board of directors, in a private transaction. F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust. |
| Common StockSEC Table I · non-derivative | IndirectBy IRA | 3,941 |
Reported balance
Holding disclosure · report date 2024-12-03 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 3,941 |
| Common StockSEC Table I · non-derivative | IndirectBy Patience Enterprises LP | 214,046 |
Reported balance
Holding disclosure · report date 2024-12-03 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 214,046 F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares purchased by the reporting person from Jack Schuler, a member of the issuer's board of directors, in a private transaction.
F2: The reporting person has sole voting and dispositive power with respect to such shares in his capacity as trustee of the trust.
F3: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.
BIODESIX INC
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 26,743 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 1,360 · Balance 26,743 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 1,361 |
Reported balance
After 2026-09-30 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-09-30 · Exercise / conversion · Disposed 1,360 · Balance 1,361 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock"). F4: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. |
| Common StockSEC Table I · non-derivative | IndirectBy Patience Enterprises LP | 107,664 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 107,664 F2: The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose. |
| Common StockSEC Table I · non-derivative | IndirectBy John Patience Living Trust dated 7/23/1993 | 241,480 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 241,480 F3: The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993). |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 2,649 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 2,649 |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's common stock ("Common Stock").
F2: The Reporting Person is the sole general partner of Patience Enterprises LP. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of the reported securities for purposes of Section 16 or for any other purpose.
F3: The Reporting Person is the sole trustee of John Patience Living Trust (July 23, 1993).
F4: These RSUs vest in four substantially equal installments on March 31, June 30, September 30 and December 31, 2026, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
STERICYCLE INC
Report date May 23, 2018 · Filed May 25, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 3,878 |
Reported balance
After 2018-05-23 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-05-23 · Grant · Acquired 1,970 · Balance 3,878 F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 07, 2020 Filed Dec 10, 2020 02:39 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionStock Options (Right to Buy) · Derivative | 23,440 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0000905148-20-001262 · form4.xml · derivative · entry 7 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,718 Underlying: Common Stock · 23,440 shares Expires 2030-04-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option vests in 12 successive, equal monthly installments measured from April 1, 2020. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 02:39 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionStock Options (Right to Buy) · Derivative | 35,157 | $0.00 Strike: $6.83 | $0.00 |
DisclosureSEC source: 0000905148-20-001262 · form4.xml · derivative · entry 6 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1 Underlying: Common Stock · 35,157 shares Expires 2029-07-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vested in 12 successive, equal monthly installments measured from April 1, 2019. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 02:39 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 23,440 | $6.83 | $160,095.20 |
DisclosureSEC source: 0000905148-20-001262 · form4.xml · nonDerivative · entry 2 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,597 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 07, 2020 Filed Dec 10, 2020 02:39 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 35,157 | $6.83 | $240,122.31 |
DisclosureSEC source: 0000905148-20-001262 · form4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | Conversion3% Convertible Debt due June 2021 · Derivative | Not disclosed | $0.00 Strike: $14.40 | $900,000.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 21 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 0 Underlying: Common Stock · 64,416 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Upon completion of the IPO, the outstanding principal and unpaid accrued interest on this Convertible Debt was automatically converted into Common Stock. Share numbers gave effect to such conversion; debt amount reflects principal only, no interest. F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | Conversion3% Convertible Debt due June 2021 · Derivative | Not disclosed | $0.00 Strike: $14.40 | $1,150,000.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 20 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 0 Underlying: Common Stock · 81,600 shares Expires 2021-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F7 · derivative.exercise_date: Upon completion of the IPO, the outstanding principal and unpaid accrued interest on this Convertible Debt was automatically converted into Common Stock. Share numbers gave effect to such conversion; debt amount reflects principal only, no interest. F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries H Preferred Stock · Derivative | 4,182,413 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 18 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 0 Underlying: Common Stock · 704,596 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries G Preferred Stock · Derivative | 6,711,816 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 17 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 0 Underlying: Common Stock · 1,130,715 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries G Preferred Stock · Derivative | 957,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 16 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 0 Underlying: Common Stock · 161,242 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries F Preferred Stock · Derivative | 3,055,837 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 15 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 0 Underlying: Common Stock · 514,806 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries F Preferred Stock · Derivative | 3,205,681 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 14 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 0 Underlying: Common Stock · 540,050 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries E Preferred Stock · Derivative | 1,484,624 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 13 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 0 Underlying: Common Stock · 250,109 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries E Preferred Stock · Derivative | 809,200 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 12 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 0 Underlying: Common Stock · 136,323 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries D Preferred Stock · Derivative | 2,932,534 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 11 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 0 Underlying: Common Stock · 494,033 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries D Preferred Stock · Derivative | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 10 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 0 Underlying: Common Stock · 42,117 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries C Preferred Stock · Derivative | 666,666 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 9 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 0 Underlying: Common Stock · 112,311 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries B-1 Preferred Stock · Derivative | 1,250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 8 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 0 Underlying: Common Stock · 245,041 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers gave effect to such conversion. The B-1 Preferred Stock had no expiration date. F4 · derivative.exercise_date: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers gave effect to such conversion. The B-1 Preferred Stock had no expiration date. F4 · derivative.expiration_date: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers gave effect to such conversion. The B-1 Preferred Stock had no expiration date. F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionSeries B Preferred Stock · Derivative | 1,454,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 7 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 0 Underlying: Common Stock · 245,042 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 30,000 | $18.00 | $540,000.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · nonDerivative · entry 6 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 30,000 Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionCommon Stock | 64,416 | $14.40 | $927,590.40 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · nonDerivative · entry 5 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 2,811,431 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionCommon Stock | 81,600 | $14.40 | $1,175,040.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · nonDerivative · entry 4 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 1,910,968 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionCommon Stock | 245,041 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · nonDerivative · entry 3 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 2,747,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: Every share of Series B-1 Preferred Stock ("B-1 Preferred Stock") converted into approximately 0.196 shares of Common Stock at the closing of the Issuer's IPO. Share numbers gave effect to such conversion. The B-1 Preferred Stock had no expiration date. F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionCommon Stock | 2,501,974 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · nonDerivative · entry 2 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 2,501,974 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F3 · ownership.direct: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). F3 · ownership.nature: The reporting person is the sole trustee of John Patience Trust (July 23, 1993). Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | ConversionCommon Stock | 1,829,368 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 1,829,368 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Every share of Series B Preferred Stock, Series C Preferred Stock, Series D Preferred Stock, Series E Preferred Stock, Series F Preferred Stock, Series G Preferred Stock and Series H Preferred Stock, (collectively, the "Preferred Stock") converted into approximately 0.1684664 shares of Issuer Common Stock ("Common Stock") at the closing of the Issuer's initial public offering ("IPO"). Share numbers gave effect to such conversion. The Preferred Stock had no expiration date. F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| June 23, 2020 Filed Nov 3, 2020 23:25 UTC | BIODESIX INC BDSX · Entity 6053 | Grant3% Convertible Debt due June 2021 · Derivative | Not disclosed | $0.00 | $150,000.00 |
DisclosureSEC source: 0001209191-20-056752 · doc4.xml · derivative · entry 19 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner · Chairman 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 1,150,000 Underlying: Common Stock · 10,527 shares Expires 2021-06-30 F5 · derivative.exercise_price: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F6 · date: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F6 · kind: This transaction occurred prior to the Issuer's initial public offering and is being reported on Form 4 solely for purposes of compliance with Rule 16a-2(a) under the Securities Exchange Act of 1934, as amended. The securities covered by such transaction were previously included on the Reporting Person's Form 3. F5 · derivative.exercise_date: This Convertible Debt paid interest at 3% per annum and was payable in full upon maturity through the conversion to Series H Preferred Stock at 80% of the original issuance price of $1.15 per share. On or before the maturity date and if the Convertible Debt remained unpaid, the outstanding principal and unpaid accrued interest was to be automatically converted into Common Stock at the completion of the IPO at a conversion price equal to 80% of the price per share paid for the Common Stock sold in the IPO. Share numbers give effect to such conversion; debt amount reflects principal only, no interest. F2 · ownership.direct: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. F2 · ownership.nature: The reporting person is the sole general partner of Patience Enterprises LP. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| April 01, 2020 Filed Apr 3, 2020 12:21 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantStock Option (right to buy) · Derivative | 13,779 | $0.00 Strike: $8.33 | $0.00 |
DisclosureSEC source: 0001628280-20-004571 · wf-form4_158593084397620.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,779 Underlying: Common Stock · 13,779 shares Expires 2030-04-01 F1 · derivative.exercise_date: The option vests in twelve equal monthly installments, with the first installment vesting on May 1, 2020. Read SEC document |
| March 24, 2020 Filed Mar 26, 2020 15:35 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 5,000 | $6.83 | $34,150.00 |
DisclosureSEC source: 0001628280-20-004093 · wf-form4_158525130138977.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Trust dated 7/23/1993 Disclosed balance after: 4,196,211 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.81 to $6.85, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. Read SEC document |
| March 24, 2020 Filed Jul 31, 2020 18:16 UTC Amendment | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 5,000 | $6.83 | $34,150.00 |
DisclosureSEC source: 0001628280-20-011379 · wf-form4a_159623377007067.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Living Trust dated 7/23/1993 Disclosed balance after: 4,300,481 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.81 to $6.85, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc. (the "Issuer"), any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (1) to this Form 4. F2 · balance_after: Due to a clerical error, the reported shares owned indirectly by the reporting person through the John Patience Living Trust dated 7/23/1993 (the "Trust") has been adjusted to correct an understatement of 104,270 shares. The 104,270 shares represent (i) 59,600 shares acquired by the Trust on May 2, 2014, which were previously reported in the reporting person's Form 4 filed May 2, 2014 and inadvertently omitted in subsequent filings; (ii) 20,000 shares acquired by the Trust on December 1, 2016, which were incorrectly reported as acquired directly by the reporting person in the reporting person's Form 4 filed December 7, 2016 and in subsequent filings; and (iii) 24,670 shares acquired by the Trust on December 13, 2016, which were incorrectly reported as acquired directly by the reporting person in the reporting person's Form 4 filed December 14, 2016 and in subsequent filings. Read SEC document |
| April 01, 2019 Filed Mar 27, 2020 21:04 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantStock Option (right to buy) · Derivative | 12,290 | $0.00 Strike: $21.02 | $0.00 |
DisclosureSEC source: 0001628280-20-004263 · wf-form4_158535748088342.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,290 Underlying: Common Stock · 12,290 shares Expires 2029-04-01 F1 · date: This Form 4 was inadvertently not filed within the required time following the transaction date of April 1, 2019. F2 · derivative.exercise_date: The option vests in twelve equal monthly installments, with the first installment vesting on May 1, 2019. Read SEC document |
| November 08, 2018 Filed Nov 13, 2018 21:40 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 10,000 | $14.96 | $149,600.00 |
DisclosureSEC source: 0001144204-18-059492 · tv506947_4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Defined Benefit Pension Plan Disclosed balance after: 39,411 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $14.96 to $15.00, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold in each separate price within the range. Read SEC document |
| May 23, 2018 Filed May 24, 2018 16:51 UTC | STERICYCLE INC SRCL · Entity 80873 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 7,105 | $0.00 Strike: $58.82 | $0.00 |
DisclosureSEC source: 0001692742-18-000076 · edgardoc.xml · derivative · entry 4 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,105 shares Expires 2018-05-29 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2018 Filed May 24, 2018 16:51 UTC | STERICYCLE INC SRCL · Entity 80873 | SaleCommon Stock | 6,624 | $63.15 | $418,281.09 |
DisclosureSEC source: 0001692742-18-000076 · edgardoc.xml · nonDerivative · entry 2 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,110 Read SEC document |
| May 23, 2018 Filed May 24, 2018 16:51 UTC | STERICYCLE INC SRCL · Entity 80873 | Exercise / conversionCommon Stock | 7,105 | $58.82 | $417,916.10 |
DisclosureSEC source: 0001692742-18-000076 · edgardoc.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,734 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 23, 2018 Filed May 25, 2018 16:08 UTC | STERICYCLE INC SRCL · Entity 80873 | GrantRestricted Stock Units · Derivative | 1,970 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001692742-18-000090 · edgardoc.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,878 Underlying: Common Stock · 1,970 shares Expires not disclosed F1 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. F1 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. Read SEC document |
| April 30, 2018 Filed May 2, 2018 17:19 UTC | STERICYCLE INC SRCL · Entity 80873 | GrantRestricted Stock Units · Derivative | 170 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-006059 · edgar.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,078 Underlying: Common Stock · 170 shares Expires not disclosed F1 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. F1 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. Read SEC document |
| April 01, 2018 Filed Apr 3, 2018 15:13 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantStock Option (right to buy) · Derivative | 9,476 | $0.00 Strike: $22.85 | $0.00 |
DisclosureSEC source: 0001144204-18-018911 · tv490260_4.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,476 Underlying: Common Stock · 9,476 shares Expires 2028-04-01 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments, with the first installment vesting on May 1, 2018. Read SEC document |
| January 31, 2018 Filed Feb 1, 2018 17:00 UTC | STERICYCLE INC SRCL · Entity 80873 | GrantRestricted Stock Units · Derivative | 132 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001692742-18-000012 · edgardoc.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,908 Underlying: Common Stock · 132 shares Expires not disclosed F1 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. F1 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. Read SEC document |
| November 07, 2017 Filed Nov 9, 2017 15:00 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 20,000 | $18.75 | $375,000.00 |
DisclosureSEC source: 0001144204-17-057662 · tv479096_4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Trust dated 7/23/1993 Disclosed balance after: 4,191,211 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.73 to $18.75, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 06, 2017 Filed Nov 8, 2017 15:03 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 38,700 | $18.61 | $720,207.00 |
DisclosureSEC source: 0001144204-17-057234 · tv478969_4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Trust dated 7/23/1993 Disclosed balance after: 4,171,211 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $18.50 to $18.63, inclusive. The reporting person undertakes to provide to Accelerate Diagnostics, Inc., any shareholder of Accelerate Diagnostics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 18:22 UTC | STERICYCLE INC SRCL · Entity 80873 | GrantRestricted Stock Units · Derivative | 141 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001692742-17-000056 · edgardoc.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,776 Underlying: Common Stock · 141 shares Expires not disclosed F1 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. F1 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer actual receipt of the shares to which such person would otherwise be entitled upon vesting until such person's separation of service from the issuer. Read SEC document |
| July 31, 2017 Filed Aug 1, 2017 17:53 UTC | STERICYCLE INC SRCL · Entity 80873 | GrantRestricted Stock Units · Derivative | 129 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001692742-17-000049 · edgardoc.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,635 Underlying: Common Stock · 129 shares Expires not disclosed F1 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer receipt of the shares to which such person would otherwise be entitled upon vesting until such persons separation of service from the issuer. F1 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer receipt of the shares to which such person would otherwise be entitled upon vesting until such persons separation of service from the issuer. Read SEC document |
| May 25, 2017 Filed May 26, 2017 16:36 UTC | STERICYCLE INC SRCL · Entity 80873 | Exercise / conversionRestricted Stock Units · Derivative | 495 | Not disclosed Strike: $0.00 | Not disclosed |
DisclosureSEC source: 0001692742-17-000030 · edgardoc.xml · derivative · entry 3 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 495 shares Expires 2017-05-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date. F1 · price: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date. F1 · derivative.exercise_date: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date. F1 · derivative.expiration_date: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| May 25, 2017 Filed May 26, 2017 16:36 UTC | STERICYCLE INC SRCL · Entity 80873 | Exercise / conversionCommon Stock | 495 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001692742-17-000030 · edgardoc.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,629 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit(RSU) represents the right to receive, at settlement, one share of common stock. This transaction represents the full vesting of RSUs in shares of common stock on their scheduled vesting date. Read SEC document |
| May 24, 2017 Filed May 26, 2017 16:36 UTC | STERICYCLE INC SRCL · Entity 80873 | GrantRestricted Stock Units · Derivative | 1,506 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001692742-17-000030 · edgardoc.xml · derivative · entry 4 PATIENCE JOHN · CIK 0001021413 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,506 Underlying: Common Stock · 1,506 shares Expires not disclosed F2 · derivative.exercise_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer receipt of the shares to which such person would otherwise be entitled upon vesting until such persons separation of service from the issuer. F2 · derivative.expiration_date: In accordance with the Stericycle, Inc. Directors Deferred Stock Plan, the reporting person has elected to defer receipt of the shares to which such person would otherwise be entitled upon vesting until such persons separation of service from the issuer. Read SEC document |
| April 01, 2017 Filed Apr 4, 2017 19:07 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | GrantStock Option (right to buy) · Derivative | 11,721 | $0.00 Strike: $24.20 | $0.00 |
DisclosureSEC source: 0001144204-17-018992 · v463574_4.xml · derivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,721 Underlying: Common Stock · 11,721 shares Expires 2027-04-01 F1 · derivative.exercise_date: The option vests in 12 equal monthly installments, with the first installment vesting on May 1, 2017. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 19:31 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 39,500 | $19.00 | $750,500.00 |
DisclosureSEC source: 0001144204-17-001696 · v456704_4.xml · nonDerivative · entry 2 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By Patience Enterprises LP Disclosed balance after: 2,110,662 F1 · ownership.nature: The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose. Read SEC document |
| January 09, 2017 Filed Jan 10, 2017 19:31 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | PurchaseCommon Stock | 13,200 | $19.00 | $250,800.00 |
DisclosureSEC source: 0001144204-17-001696 · v456704_4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Indirect · By John Patience Trust dated 7/23/1993 Disclosed balance after: 4,132,511 Read SEC document |
| December 13, 2016 Filed Dec 14, 2016 16:35 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionStock Option (right to buy) · Derivative | 24,670 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001144204-16-139501 · v455035_4.xml · derivative · entry 5 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,670 shares Expires 2023-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2016 Filed Dec 14, 2016 16:35 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionCommon Stock | 24,670 | $6.48 | $159,861.60 |
DisclosureSEC source: 0001144204-16-139501 · v455035_4.xml · nonDerivative · entry 1 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,670 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 01, 2016 Filed Dec 7, 2016 20:55 UTC | Accelerate Diagnostics, Inc AXDX · Entity 78156 | Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $6.48 | $0.00 |
DisclosureSEC source: 0001144204-16-138466 · v454647_4.xml · derivative · entry 5 PATIENCE JOHN · CIK 0001021413 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,670 Underlying: Common Stock · 20,000 shares Expires 2023-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: The total number of stock options held by the reporting person was previously aggregated in Table II of the reporting person's previous Form 4s. The number of stock options reported on this Form 4 reflects only the number of stock options of the class reported herein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.